
De onderzoekers evalueerden panitumumab plus mFOLFOX in 91 patiënten (cohort A) en panitumumab plus fluoruracil-leucovorine in 92 patiënten (cohort B). In beide cohorten kregen de patiënten twaalf cycli behandeling, gevolgd door panitumumab-onderhoudsbehandeling. Het primaire eindpunt was progressievrije overleving. In beide cohorten was de nulhypothese een mediane PFS van 6 maanden of lager.
De mediane follow-up was 50,0 maanden (IQR 45,6-56,4). De figuur laat zien dat de mediane PFS 9,6 maanden was in cohort A en 9,0 maanden in cohort B (p<0,001 in beide cohorten). De overall response rate was 69% in cohort A en 52% in cohort B. De mediane overall survival was 23,5 maanden in cohort A en 22,0 maanden in cohort B. Graad 2 of hoger chemotherapie-gerelateerde adverse events was 60% in cohort A en 37% in cohort B.
De onderzoekers concluderen dat de combinaties panitumumab-mFOLFOX en panitumumab-fluorouracil-leucovorine redelijke eerstelijns opties zijn voor niet-resectabel RAS-/BRAF-wildtype mCRC in 70-plussers.
1.Lonardi S, Rasola C, Lobefaro R et al. Initial panitumumab plus fluorouracil, leucovorin, and oxaliplatin of plus fluorouracil and leucovorin in elderly patients with RAS and BRAF wild-type metastatic colorectal cancer: the PANDA trial by GONO Foundation. J Clin Oncol 2023; epub ahead of print
Summary: The multicenter phase 2 PANDA trial in Italy found that the combinations of panitumumab-mFOLFOX and panitumumab-fluorouracil-leucovorin are reasonable first-line options for RAS/BRAF wildtype metastatic colorectal cancer in patients aged 70 years or older.